Categories: All postsAnalystsIT

Converge Technology is a Top Pick, says Echelon

Ahead of third quarter results from Converge Technology Solutions (Converge Technology Solutions Stock Quote, Charts, News, Analysts, Financials TSX:CTS), Echelon Capital Markets analyst Rob Goff trimmed his target price on the stock in a Thursday report to clients while maintaining Converge as a Top Pick with strong organic growth prospects.

IT solutions provider Converge is set to deliver its Q3 report on November 8 after market close, while Goff is being a bit more conservative on the quarterly numbers, maintaining his revenue call at $617 million but lowering his EBITDA forecast from $39.5 million to $32.2 million (compared to the consensus call at $39.9 million). Goff said higher SG&A costs related to acquisitions are part of the issue along with a seasonally weaker quarter. 

Looking further ahead, Goff has also brought down his fourth quarter topline from $801.8 million to $785.0 million and EBITDA from $61.5 million to $54.1 million, while for 2023, he is now projecting revenue of $3.175 billion, down $164.1 million, and EBITDA of $219.1 million, also trimmed by $6.3 million.

“We are adopting a conservative stance in part to reflect macro-political and economic conditions. We hold the potential for revenue and in turn EBITDA outperformance as supply chain constraints are removed and the $507 million pipeline of firm contracts moves to booked revenues. We would look for the pipeline to move towards more normalized levels approaching $200 million. We realize that transacting against its pipeline could represent ~10 per cent growth in 2023 revenues where constraints are sufficiently removed,” Goff wrote.

With the revised numbers, Goff has maintained a “Speculative Buy” rating on CTS while dropping his target from $12.00 to $11.00, which at the time of publication represented a projected one-year return of 63 per cent. Converge’s share price has been sliding for much of 2022, with the stock currently down about 45 per cent year-to-date and down about 49 per cent for the past 12 months.

Goff said his still-bullish thesis on Converge connects with a projected 13 per cent 2023 free cash flow yield, which he said can provide downside support and “tremendous flexibility” for the company’s active M&A program and share buybacks. Goff said he could even see management introducing a modest dividend in 2023, projecting that a five per cent yield dividend would represent about one-third of the company’s free cash flow, leaving the company enough for further acquisitions. 

“We look for CTS’s well-proven copy/paste/accrete formula to maintain its cadence in H223 as it becomes further refined with vertical specialization and cross-sector service capabilities emerging into focus,” Goff wrote. 

“We look for existing concerns around organic growth to be positively addressed where double-digit organic revenue and profit emerge following the integration of recent acquisitions and a higher degree of cross-selling from vertical specialization. With an easing of supply chain headwinds, we see CTS drawing down on its $475 million backlog posting strong double-digit organic growth,” he said.

Tagged with: cts
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Auxly Cannabis is a winner, this analyst says

Haywood Securities analyst Neal Gilmer raised his target for Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts,… [Read More]

3 days ago

RBC raises price target on CGI Group to $115.00

RBC Dominion Securities analyst Paul Treiber raised his target for CGI (CGI Stock Quote, Chart, News, Analysts, Financials TSX:GIB.A) to… [Read More]

3 days ago

Why is inflation so bad in Atlantic Canada?

Inflation is running above 3% in eight Canadian provinces, with Atlantic Canada facing some of the strongest price pressures as… [Read More]

3 days ago

Analyst chops target on goeasy (TSX:GSY)

National Bank Financial analyst Jaeme Gloyn lowered his target for goeasy (goeasy Stock Quote, Chart, News, Analysts, Financials TSX:GSY) to… [Read More]

3 days ago

Gain Therapeutics: this analyst just chopped his target

Roth Capital Partners analyst Boobalan Pachaiyappan lowered his target on Gain Therapeutics (Gain Therapeutics Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 days ago

WELLSTAR Technologies is off to a great start, this analyst says

WELLSTAR Technologies’ (WELLSTAR Technologies Corp. Stock Quote, Chart, News, Analysts, Financials TSXV:WSTR) first quarterly results as a public company exceeded… [Read More]

3 days ago